NR4A1 and neoplasm: The EGFR inhibitor gefitinib presented a low clinical benefit rate (CBR) and virtually no tumor response in patients with advanced breast cancer (ABC), regardless of whether their tumors were hormone receptor positive or hormone receptor negative.6